The Big and the Small: Development of the Next-Generation Antibody-based Therapeutics

Tianlei Ying*

131 Dong An Rd
Fudan University
Shanghai, China

Therapeutic modalities based on monoclonal antibodies (mAbs) have shown clinical success in the treatment of many diseases. By using extraordinarily large human antibody libraries and in vitro display technologies including a novel phage-mammalian-combined display strategy, we have identified a number of potent neutralizing mAbs against cancer and infectious diseases. We have also been working on the development of novel antibody constructs with varying size (from 14 kDa to 180 kDa), with the purpose of engineering safer, cheaper, and more potent next-generation antibody-based therapeutics.

Biographic Details

Tianlei Ying

Professor        

Fudan University, China

Phone: +86 2154237761 Fax: +86 2154237761  E-mail: tlying@fudan.edu.cn

Research interests: antibody engineering, CAR-T, infectious diseases